Current state of therapeutic focused ultrasound applications in neuro-oncology

Meng, Ying; Pople, Christopher B; Budiansky, Dan; Li, Daniel; Suppiah, Suganth; Lim-Fat, Mary Jane; Perry, James; Sahgal, Arjun; Lipsman, Nir

doi:10.1007/s11060-021-03861-0

Cited by 18 publications

(14 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HIFU is a type of ultrasound-based treatment method, thus the specific therapeutics used for HIFU have acoustic properties, which makes ultrasounds one of the first choices for monitoring of HIFU. However, given that diagnostic and therapeutic ultrasound have different frequencies ( 98 , 99 ), the acoustic properties of the therapeutics may respond to only one type of ultrasound. Therefore, it is important to design therapeutics that are responsive to both diagnostic and therapeutic ultrasound.…”

Section: Nano-based Hifu Cancer Theranosticsmentioning

confidence: 99%

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Zheng¹,

Xia²,

Huang³

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

High-intensity focused ultrasound (HIFU) is a promising and representative non-invasive therapeutic method for treating cancer with a high degree of efficacy. This non-invasive method induces tumour cell necrosis by increasing the local temperature and mechanical pressure. However, the clinical application of HIFU is limited given its low penetration depth and the incidence of off-target side effects. With their promising structural adjustability and targeting ability, nanomedicines have been adopted to improve the ablative efficacy of HIFU in the treatment of cancer. By selectively changing the acoustic environment (tissue structure, density and blood supply) of tumour tissue, these nanomedicines may allow for lower HIFU doses and treatment duration, while additionally achieving a higher degree of efficacy. The use of nanomedicines may also enable cancer theranostics of HIFU, allowing for precise cancer therapeutics. The present review aimed to provide an overview of advances in nanomedicines for HIFU cancer treatment and theranostics, stating their current limitations and future perspectives. Contents 1. Introduction 2. Nano-therapeutics for HIFU-based cancer treatment 3. Nano-based HIFU cancer theranostics 4. Conclusions and future perspectives

show abstract

Section: Nano-based Hifu Cancer Theranosticsmentioning

confidence: 99%

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Zheng¹,

Xia²,

Huang³

et al. 2023

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…Hence, FDA-approval intent clinical trials are underway studying combining MR-guided LIFU with systemic therapies. 38 39…”

Section: Novel Local Therapiesmentioning

confidence: 99%

Management of Brain Metastases: A Review of Novel Therapies

Bellur,

Khosla,

Ozair

et al. 2023

Semin Neurol

View full text Add to dashboard Cite

Brain metastases (BMs) represent the most common intracranial tumors in adults, and most commonly originate from lung, followed by breast, melanoma, kidney, and colorectal cancer. Management of BM is individualized based on the size and number of brain metastases, the extent of extracranial disease, the primary tumor subtype, neurological symptoms, and prior lines of therapy. Until recently, treatment strategies were limited to local therapies, like surgical resection and radiotherapy, the latter in the form of whole-brain radiotherapy or stereotactic radiosurgery. The next generation of local strategies includes laser interstitial thermal therapy, magnetic hyperthermic therapy, post-resection brachytherapy, and focused ultrasound. New targeted therapies and immunotherapies with documented intracranial activity have transformed clinical outcomes. Novel systemic therapies with intracranial utility include new anaplastic lymphoma kinase inhibitors like brigatinib and ensartinib; selective “rearranged during transfection” inhibitors like selpercatinib and pralsetinib; B-raf proto-oncogene inhibitors like encorafenib and vemurafenib; Kirsten rat sarcoma viral oncogene inhibitors like sotorasib and adagrasib; ROS1 gene rearrangement (ROS1) inhibitors, anti-neurotrophic tyrosine receptor kinase agents like larotrectinib and entrectinib; anti-human epidermal growth factor receptor 2/epidermal growth factor receptor exon 20 agent like poziotinib; and antibody–drug conjugates like trastuzumab-emtansine and trastuzumab-deruxtecan. This review highlights the modern multidisciplinary management of BM, emphasizing the integration of systemic and local therapies.

show abstract

“…Focused ultrasound (FUS) causes intravenously administered microbubbles to oscillate in the applied low-energy ultrasound field, thereby increasing the BBB permeability by the shear stress mechanism. This modality is gaining interest because it can allow chemotherapeutic agents, especially those with a large molecular weight, to achieve higher concentrations in the tumor tissue [ 187 ]. The safety and feasibility of FUS were first established in a study of 5 patients with high-grade gliomas.…”

Section: Current Approach To Newly Diagnosed Gbmmentioning

confidence: 99%

Updates in IDH-Wildtype Glioblastoma

et al. 2022

Self Cite

View full text Add to dashboard Cite

Glioblastoma is the most aggressive primary brain tumor with a poor prognosis. The 2021 WHO CNS5 classification has further stressed the importance of molecular signatures in diagnosis although therapeutic breakthroughs are still lacking. In this review article, updates on the current and novel therapies in IDH-wildtype GBM will be discussed. Supplementary Information The online version contains supplementary material available at 10.1007/s13311-022-01251-6.

show abstract

Current state of therapeutic focused ultrasound applications in neuro-oncology

Cited by 18 publications

References 85 publications

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Nanomedicines for high‑intensity focused ultrasound cancer treatment and theranostics (Review)

Management of Brain Metastases: A Review of Novel Therapies

Updates in IDH-Wildtype Glioblastoma

Contact Info

Product

Resources

About